Clinical Trial Update: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients. [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory trial evaluating the safety and efficacy of intravenous Anti-CD20/CD30-CAR-T cell therapy in relapsed/refractory lymphoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Anti-CD20/CD30-CAR-T cell infusion (CD20/CD30-targeted CAR-T cell therapy)

Snippet

Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine | Conditions: B Cell Malignancies | EARLY_Phase 1 | Status: NOT_YET_RECRUITING